MÓDULO

1

Lección 5. Variantes tumefactivas y agresivas de la esclerosis múltiple
Cristina Ramo Tello1, Anna Massuet Vilamajó2

1 Unidad de Esclerosis Múltiple y Neuroinmunología. Departamento de Neurociencias. Hospital Universitario Germans Trias i Pujol. Badalona, Barcelona; 2 Instituto de Diagnóstico por la Imagen (IDI). Hospital Universitario Germans Trias i Pujol. Badalona, Barcelona

Referencias bibliográficas

  1. Patriarca L, Torlone S, Ferrari F, Di Carmine C, Totaro R, di Cesare E, Splendiani A. Is size an essential criterion to define tumefactive plaque? MR features and clinical correlation in multiple sclerosis. Neuroradiol J. 2016 Oct;29(5):384-9. [Pubmed]
  2. Altintas A, Petek B, Isik N, Terzi M, Bolukbasi F, Tavsanli M, et al. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler. 2012 Oct;18(10):1448-53. [Pubmed]
  3. Masdeu JC, Quinto C, Olivera C, Tenner M, Leslie D, Visintainer P. Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology. 2000 Apr 11;54(7):1427-33. [Pubmed]
  4. Given CA 2nd, Stevens BS, Lee C. The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol. 2004 Jan;182(1):195-9. [Pubmed]
  5. Cha S, Pierce S, Knopp EA, Johnson G, Yang C, Ton A, et al. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol. 2001 Jun-Jul;22(6):1109-16. [Pubmed]
  6. Majós C, Aguilera C, Alonso J, Julià-Sapé M, Castañer S, Sánchez JJ, et al. Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR Am J Neuroradiol. 2009 Mar;30(3):544-51. [Pubmed]
  7. Cianfoni A, Niku S, Imbesi SG. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol. 2007 Feb;28(2):272-7. [Pubmed]
  8. Schiepers C, Van Hecke P, Vandenberghe R, Van Oostende S, Dupont P, Demaerel P, et al. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler. 1997 Feb;3(1):8-17. [Pubmed]
  9. Hardy TA, Chataway J. Tumefactive demyelination: an approach to diagnosis and management. J Neurol Neurosurg Psychiatry. 2013 Sep;84(9):1047-53. [Pubmed]
  10. Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999 Dec;46(6):878-86. [Pubmed]
  11. Rubio-Guerra S, Massuet-Vilamajó A, Presas-Rodríguez S, Ramo-Tello C. Catastrophic demyelinating multifocal encephalitis. Neurologia (Engl Ed). 2021 Apr 7:S0213-4853(21)00042-6. Epub ahead of print. [Pubmed]
  12. Ortega-Sierra MG, Delgado-Marrugo RD, Campo-Bedoya CC, Marín-Pérez G, Gómez-Caballero R, Hernández-Nieto BD, et al. Tumefactive multiple sclerosis: a rare but serious variable in multiple sclerosis. Rom Neurosurg. 2021;35(4):538-43. Disponible en: [Enlace]
  13. Di Gregorio M, Torri Clerici VLA, Fenu G, Gaetani L, Gallo A, Cavalla P, et al. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. Eur J Neurol. 2021 Apr;28(4):1299-307. [Pubmed]
  14. Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, Weigand S, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008 Jul;131(Pt 7):1759-75. [Pubmed]
  15. Frederick MC, Cameron MH. Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders. Curr Neurol Neurosci Rep. 2016 Mar;16(3):26. [Pubmed]
  16. Totaro R, Di Carmine C, Splendiani A, Torlone S, Patriarca L, Carrocci C, et al. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis. Neurol Sci. 2016 Jul;37(7):1113-7. [Pubmed]
  17. Sánchez P, Meca-Lallana V, Barbosa A, Manzanares R, Palmí I, Vivancos J. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature. J Neurol Sci. 2017 Oct 15;381:32-38. [Pubmed]
  18. Hardy TA, Chataway J. Tumefactive demyelination: an approach to diagnosis and management. J Neurol Neurosurg Psychiatry. 2013 Sep;84(9):1047-53. [Pubmed]
  19. Villarreal JV, Abraham MJ, Acevedo JAG, Rai PK, Thottempudi N, Fang X, Gogia B. Tumefactive multiple sclerosis (TMS): A case series of this challenging variant of MS. Mult Scler Relat Disord. 2021 Feb;48:102699. [Pubmed]
  20. Sánchez P, Meca-Lallana V, Vivancos J. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases. Mult Scler Relat Disord. 2018 Oct;25:95-98. [Pubmed]
  21. Moghadasi AN, Baghbanian SM. Tumefactive demyelinating lesions in a patient with multiple sclerosis receiving natalizumab. Acta Neurol Belg. 2019 Mar;119(1):137-9. [Pubmed]
  22. Jander S, Turowski B, Kieseier BC, Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler. 2012 Nov;18(11):1650-2. [Pubmed]
  23. Wehrum T, Beume LA, Stich O, Mader I, Mäurer M, Czaplinski A, et al. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. Neurology. 2018 Feb 13;90(7):e601-e605. [Pubmed]
  24. Hyun JW, Kim Y, Kim G, Kim SH, Kim HJ. Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis. Mult Scler. 2019 Dec;25(14):1942-5. [Pubmed]
  25. Zhu N, Presas-Rodríguez S, Núñez-Marín F, Quirant-Sánchez B, Ramo-Tello C. Single pseudotumour lesion, a rare debut presentation of optic neuromyelitis spectrum disorder. Neurologia (Engl Ed). 2021 Jun;36(5):396-8. [Pubmed]
  26. Ataka T, Kimura N, Matsubara E. A case of myelin oligodendrocyte glycoprotein-antibody-associated disease presenting with tumefactive demyelinating lesion. Mult Scler Relat Disord. 2020 Aug;43:102191. [Pubmed]
  27. Zettl UK, Stüve O, Patejdl R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev. 2012 Jan;11(3):167-73. [Pubmed]
  28. Stadelmann C, Ludwin S, Tabira T, Guseo A, Lucchinetti CF, Leel-Ossy L, et al. Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain. 2005 May;128(Pt 5):979-87. [Pubmed]
  29. Xie JS, Jeeva-Patel T, Margolin E. Baló's concentric sclerosis - A rare entity within the spectrum of demyelinating diseases. J Neurol Sci. 2021 Sep 15;428:117570. [Pubmed]
  30. Hu W, Lucchinetti CF. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol. 2009 Nov;31(4):439-53. [Pubmed]
  31. Wood DD, Bilbao JM, O'Connors P, Moscarello MA. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol. 1996 Jul;40(1):18-24. [Pubmed]
  32. Vakrakou AG, Tzanetakos D, Argyrakos T, Koutsis G, Evangelopoulos ME, Andreadou E, et al. Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature. Front Neurol. 2020 Jun 30;11:536. [Pubmed]
  33. Gobbin F, Marangi A, Orlandi R, Richelli S, Turatti M, Calabrese M, et al. A case of acute fulminant multiple sclerosis treated with alemtuzumab. Mult Scler Relat Disord. 2017 Oct;17:9-11. [Pubmed]
  34. Poser CM, Goutières F, Carpentier MA, Aicardi J. Schilder's myelinoclastic diffuse sclerosis. Pediatrics. 1986 Jan;77(1):107-12. Erratum in: Pediatrics 1986 Jul;78(1):138. [Pubmed]